衰变加速因子在非小细胞肺癌中的表达及其临床意义  

Expression of decay accelerating factor in non-small cell lung carcinoma and its clinical significance

作　　者：赵伟鹏[1] 朱波[1] 段玉忠[1] 叶明福[2] 陈正堂[1] 

机构地区：[1]第三军医大学新桥医院全军肿瘤中心,重庆400037 [2]第三军医大学新桥医院病理科,重庆400037

出　　处：《免疫学杂志》2006年第1期58-60,共3页Immunological Journal

基　　金：国家自然科学基金资助项目(30200120;30300150;30400407)

摘　　要：目的检测衰变加速因子(decay accelerating factor,DAF,CD55)在非小细胞肺癌(non-small cell lung carcinoma,NSCLC)中的表达,分析其表达与临床分期、化疗用药及预后的关系。方法免疫组化法检测8例NSCLC癌旁组织和36例NSCLC手术标本中DAF的蛋白表达,分析临床资料。结果免疫组化结果显示36例NSCLC标本中,共有18例(50.0%)表达DAF,其中18例肺鳞癌中有15例(83.3%)表达,而16例肺腺癌中有3例(18.8%)表达,两者有显著差异(P<0.05);不同的病理分期的DAF免疫组化平均积分光密度表达有显著性差异(P<0.05);DAF的表达与无病生存期无相关关系(P>0.05)。结论NSCLC中有DAF的表达,尤其是肺鳞癌;提示在NSCLC抗体治疗中应同时阻断DAF的免疫抑制效应。Objective To survey decay accelerating factor （DAF） expression in non-small cell lung carcinoma （NSCLC） and analyze the relationships between DAF expression and clinical staging, as well as adjuvant chemotherapy and disease-free survival. Methods The expressions of DAF in 8 adjacent tissues and 36 NSCLC samples were determined by immunohistochemistry. Furthermore, the relationships between DAF expression and clinical stage, as well as adjuvant chemotherapy and disease-free survival were assayed by follow-up. Results Among 36 samples of non-small-cell lung carcinoma, there were 18 （50.0%） samples expressing DAF. Fifteen out of 18 samples （83.3%） of squamous carcinoma expressed DAF while 3 out of 16 samples of adenocarcinoma （ 18.8% ） expressed DAF, which suggested a significant difference （ P 〈 0. 05）. There was significant difference among different clinical stages by immunohistochemisty integrate optical density （ P 〈 0.05）. There was no correlation between DAF expression and disease-flee survival （P 〉 0.05）. Conclusion There is great percentage of DAF expression in NSCLC, especially in squamous carcinoma. Our present study suggests that the immunological inhibition of DAF should be blocked when monoclonal antibody is used in the treatment of NSCLC.

关 键 词：衰变加速因子 补体依赖细胞毒作用 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]